Vetter has opened a new business office in Shanghai, China, its fourth in the Asia Pacific (APAC) region, to help increase Vetter’s presence in China. The office will support customer relations and the development of new business. The strategic move allows the company to offer support to domestic companies that plan on bringing their molecules to the global market.

Vetter supports its worldwide customer base through every phase of their injectable drug product’s lifecycle, from early development activities to commercial supply up to lifecycle initiatives.
 
“We are convinced that our continued investment in the Asia Pacific region will significantly contribute to our future global growth,” said Vetter Managing Director Peter Soelkner. “With an increased share of Asian firms among the Top 50 Pharma companies worldwide over the last several years, our mission is to service the needs of our global customer base, of course including Asia, in the best-possible way.”
 
Oskar Gold, Vetter’s Senior Vice President for Asia Pacific/Emerging Global Markets outlined the initiative: “Our presence in China demonstrates our dedication in one of the most important markets of the APAC region and will help to increase the awareness of Vetter’s services by presenting our expertise and market position onsite.”
 
Jason Zhong will serve as Business Development Manager China. As the first member of the new team in China, Mr. Zhong will lead Vetter’s business activities reporting to Ms. Chervee Ho, who is Vetter’s Director Key Account Management Asia Pacific, based in Singapore.
 
The new office, located in Puxi, Shanghai, is on Nanjing Road West in the heart of the city’s Central Business District. Its creation follows Vetter’s business development activities in its APAC regional office in Singapore, as well as in its sales offices in Japan and South Korea.